StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.
TherapeuticsMD Price Performance
TXMD stock opened at $1.59 on Monday. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $3.07. The business’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.82.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.23 million for the quarter.
Hedge Funds Weigh In On TherapeuticsMD
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Recommended Stories
- Five stocks we like better than TherapeuticsMD
- How to Start Investing in Real Estate
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Best Stocks Under $5.00
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How Can Investors Benefit From After-Hours Trading
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.